Engineering biology disrupts HIV drug manufacturing: systemic shift toward accessible, sustainable antiretrovirals
Original framing: “A cheaper, more sustainable way to manufacture breakthrough HIV drug Lenacapavir” — Phys.org
If scaled, engineering biology could reduce HIV drug costs by 70-90% globally, but this hinges on breaking patent monopolies and investing in local production hubs in Africa and Latin America. Scenario modeling suggests that without parallel reforms in trade policy and healthcare infrastructure, even cheaper drugs will remain inaccessible to marginalized groups. Future-proofing requires integrating biotech with community health systems, as seen in Rwanda’s *Mutuelles de Santé* model, which combines insurance with local governance. The risk of biotech solutions being co-opted by corporate interests remains high without democratic oversight.
The MIB’s breakthrough in Lenacapavir manufacturing exemplifies how biotechnology can disrupt entrenched systems—but only if it is disentangled from the colonial legacies of pharmaceutical capitalism.
The current narrative, while highlighting technical innovation, obscures the structural barriers that have prevented equitable access to HIV drugs for decades, from patent monopolies to the sidelining of indigenous medicinal systems. Historically, HIV interventions have succeeded when they combined scientific rigor with community-driven care, as seen in Brazil’s *saúde coletiva* model or South Africa’s Treatment Action Campaign. Yet today’s solution pathways remain fragmented, with biotech advances outpacing reforms in trade policy, healthcare infrastructure, and power dynamics. A truly systemic approach would integrate engineering biology with decolonial patent reforms, indigenous knowledge, and grassroots governance—ensuring that the next breakthrough in HIV treatment is not just cheaper or greener, but *just*. The actors driving this shift must include not only scientists and policymakers but also the very communities who have long been treated as subjects of research rather than architects of solutions.